Who is Susan Dodson DeVore and why was she appointed?

Susan Dodson DeVore has been elected as an independent director to Elevance Health's Board. Her appointment is likely intended to strengthen the board's expertise, particularly in financial matters, given her qualifications as an "audit committee financial expert" and her placement on the Audit and Finance Committees.

What impact does Ms. DeVore's appointment have on the Board's oversight?

Ms. DeVore's appointment, especially to the Audit and Finance Committees and her designation as an "audit committee financial expert," suggests a reinforcement of the company's financial governance and oversight. This can provide investors with increased confidence in the board's ability to manage financial reporting and risk.

Will Ms. DeVore's compensation be different from other directors?

No, Ms. DeVore will receive compensation in accordance with Elevance Health's standard compensation program for non-employee directors. Details of this program are available in their Form 10-Q for the quarter ended June 30, 2019.

Are there any potential conflicts of interest with Ms. DeVore's appointment?

The filing explicitly states that there are no arrangements or understandings that led to her election, nor does Ms. DeVore have any direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K. This indicates no apparent conflicts of interest at the time of her appointment.

ELV 8-K: Leadership Changes

Summary

Elevance Health, Inc. (ELV) announced a key addition to its Board of Directors. Susan Dodson DeVore has been elected as an independent director, effective immediately, with her term set to expire at the 2022 annual meeting of shareholders. This appointment is significant as it brings an experienced individual with expertise in financial oversight to the company's governance structure. Ms. DeVore's appointment includes her placement on the Audit and Finance Committees, underscoring her financial acumen. The company has confirmed she meets the qualifications of an "audit committee financial expert." Investors should note that Ms. DeVore's compensation will follow the standard program for non-employee directors. This move suggests a continued focus on robust financial governance and strategic oversight at the board level.

Key Highlights

1Susan Dodson DeVore elected as an independent director to the Board.
2Director term to expire at the 2022 annual meeting of shareholders.
3Ms. DeVore appointed to the Audit and Finance Committees.
4Ms. DeVore qualifies as an "audit committee financial expert."
5No undisclosed arrangements or material interests regarding Ms. DeVore's election.
6Compensation for Ms. DeVore will align with the standard non-employee director compensation program.

Elevance Health, Inc. 8-K Report, Executive Changes (Aug 4, 2021)

Summary

Key Highlights

Frequently Asked Questions